Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 6,514 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Cavity Clear all
Completed Phase 2 Interventional Results available

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

NCT00742859
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
betrixaban, Warfarin
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Anaheim, California • Colorado Springs, Colorado • Melbourne, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 2 Interventional

Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

NCT04870762
View directory record Official record
Conditions
Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm, Maxillary Sinus Carcinoma, Nasal Cavity Carcinoma, Oral Cavity Carcinoma, Tongue Carcinoma, Tonsillar Carcinoma
Interventions
Best Practice, Medical Device Usage and Evaluation
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NPC-12G Gel 0.2% Sirolimus PK Bridging Study

NCT03972462
View directory record Official record
Conditions
Bioavailability Study
Interventions
NPC-12G Gel 0.2%, Rapamune® 2 mg tablet
Drug
Lead sponsor
Nobelpharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT00024089
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gefitinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

NCT00243074
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
cediranib maleate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01090024
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01418339
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Santa Ana, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 4 Interventional

A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media

NCT00645112
View directory record Official record
Conditions
Acute Otitis Media
Interventions
cefdinir (Omnicef), azithromycin
Drug
Lead sponsor
Abbott
Industry
Eligibility
6 Months to 6 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
30
States / cities
Columbiana, Alabama • Montgomery, Alabama • Ozark, Alabama + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis

NCT05523765
View directory record Official record
Conditions
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
Interventions
Brepocitinib
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

NCT00782600
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
suspension IR, CR 1, CR 2, CR 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2009 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Oral Health Care Early Intervention Project

NCT00793507
View directory record Official record
Conditions
Caries
Interventions
Oral Health Care Early Intervention Project
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 36 Months
Enrollment
1,178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Aurora, Colorado • Delta, Colorado • Fort Collins, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Workflow Validation of an In-home Auto-titrating Mandibular Positioner

NCT02933112
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Auto-titrating mandibular positioner test
Device
Lead sponsor
Zephyr Sleep Technologies
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

NCT04624230
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Farmington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

NCT00279201
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 79 Years
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
138
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

NCT00746967
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
Interventions
sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
82
States / cities
Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

NCT02210000
View directory record Official record
Conditions
Gastroparesis
Interventions
Placebo, Camicinal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Chandler, Arizona • Long Beach, California • Northridge, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 3 Interventional Results available

A Study of PRN1008 in Patients With Pemphigus

NCT03762265
View directory record Official record
Conditions
Pemphigus
Interventions
Rilzabrutinib, Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Boca Raton, Florida • Coral Gables, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)

NCT01450800
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Nitrofurantoin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older · Female only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting No phase listed Observational

Biospecimen Procurement for Head and Neck Disorders

NCT03429036
View directory record Official record
Conditions
Hearing Disorder, Oral Mucosal Disease, Pharyngeal Neoplasm, Head and Neck Neoplasms, Laryngeal Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)

NCT03722966
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Oral Nicotine Replacement Therapy (NRT), Medication Reminders, Tobacco Cessation Counseling
Drug · Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion

NCT01809639
View directory record Official record
Conditions
Concussion
Interventions
Progesterone, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 44 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

NCT01403064
View directory record Official record
Conditions
Oral Mucositis
Interventions
ALD518, 0.9% saline
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

NCT04786730
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Little Rock, Arkansas • Decatur, Georgia • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 22, 2026, 10:02 AM EDT